ReviewThe oncologist2014

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Charles J Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.